New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
07:59 EDTZGNX, ESRXZogenix price target lowered to $2.50 from $5 at Oppenheimer
Oppenheimer cut its price target on Zogenix (ZGNX) after coverage of the company's Zohydro painkiller was terminated by Express Scripts (ESRX). However, the firm thinks recent disappointing news about Zogenix is already reflected in the stock. Oppenheimer keeps an Outperform rating on the shares.
News For ZGNX;ESRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 28, 2014
16:07 EDTESRXExpress Scripts sees Q4 adjusted EPS $1.36-$1.40, consensus $1.38
Sees Q4 adjusted claims 317M-337M.
16:06 EDTESRXExpress Scripts narrows FY14 EPS view to $4.86-$4.90, consensus $4.88
Subscribe for More Information
16:05 EDTESRXExpress Scripts reports Q3 adjusted EPS $1.29, consensus $1.29
Reports Q3 revenue $25.78B, consensus $24.93B. Reports Q3 adjusted claims 328.3M.
October 27, 2014
16:28 EDTZGNXVisium Asset Management reports 5.3% passive stake in Zogenix
07:34 EDTZGNXZogenix acquires Brabant Pharma for $20M cash, $15M in stock
Subscribe for More Information
October 22, 2014
09:23 EDTESRXExpress Scripts getting more aggressive on pricing, says Cleveland Research
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use